Clinical trial · Observational
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
NCT03738319CI-TRIAL-00035764unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to analyze the expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with high grade serous ovarian cancer (HGSOC) and benign gynecologic diseases. The candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Early Diagnosis | — | UNRESOLVED | — |
| Exosomes | — | UNRESOLVED | — |
| High Grade Serous Carcinoma | Ovarian Neoplasm | PROBABILISTIC | 0.70 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Prognosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sequencing of miRNA/lncRNA | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HGSOC group
- description
- This group includes patients of high grade serous ovarian cancer (HGSOC).
- interventionNames
- Genetic: Sequencing of miRNA/lncRNA
- label
- Control group
- description
- This group includes patients of benign gynecologic diseases as control.
- interventionNames
- Genetic: Sequencing of miRNA/lncRNA
Primary outcomes (1)
- measure
- Differential expression of miRNA/lncRNA
- timeFrame
- One year
- description
- Differential expression of micro-RNA (miRNA) and long non-coding RNA (lncRNA) will be compared between HGSOC group and control group, hence candidate miRNA/lncRNA will be validated as biomarker for the detection and prognosis of HGSOC.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed primary high grade serous ovarian cancer * Willing to accepted debulking surgeries and adjuvant chemotherapy * Good performance status * Aged 18 years or older * Signed an approved informed consents Exclusion Criteria: * Not meeting all of the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.